⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

August 1, 2025

Supplementary Figure 3 from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine

Ernesto Bermúdez-Abreut Gretchen Bergado Talia Fundora-Barrios Jessica Arencibia-Perezleo Armando López Medinilla Lisset Chao Belinda Sánchez-Ramírez

View at Publisher

Ask AI

Bookmark

Share

Key Points

HER1 and HER2 recognition enhances the antitumor effect of a HER3-specific monovalent vaccine.
Treatment improved the response in human tumor cell lines by utilizing HER-specific monoclonal antibodies.
The approach combines targeted therapy through vaccine development to address tumor treatment.
This strategy could lead to more effective cancer therapies by focusing on specific HER molecule interactions.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Monovalent vaccine targets HER3, showing improved antitumor effects in tumor cell lines, suggesting a strategy for cancer treatment.

Abstract

Recognition of HER1, HER2 and HER3 molecules in the membrane of different human tumor cell lines by HER‐specific monoclonal antibodies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bermúdez-Abreut et al. (2025) studied this question.

synapsesocial.com/papers/689a0c6be6551bb0af8cfc9a https://doi.org/10.1158/1535-7163.29761168

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine2025
2Supplementary Figure 2 from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine2025
3Supplementary Figure 4 from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine2025
4Data from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine2025
5Supplementary Figure 10 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
6Supplementary Figure 10 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
7Supplementary Figure S9 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)2024
8Supplementary Figure S9 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)2024